Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02846545 · ClinicalTrials.gov registry record · Phase 2
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT02846545 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 84 participants.
The verdict
NCT02846545, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if golimumab can preserve beta-cell function in children and young adults with newly diagnosed Type 1 Diabetes (T1D).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Golimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2016-08-26 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02846545
The ClinicalTrials.gov registry entry for NCT02846545 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02846545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02846545 about?
NCT02846545 is a clinical study titled "A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes". The primary purpose of this study is to determine if golimumab can preserve beta-cell function in children and young adults with newly diagnosed Type 1 Diabetes (T1D).
What is the current status of trial NCT02846545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2016-08-26. Estimated completion is 2021-01-05.
What interventions are being tested in trial NCT02846545?
The interventions under investigation include: Placebo (BIOLOGICAL), Golimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02846545?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.